- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2107934 3 comments science
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab https://www.nejm.org/doi/full/10.1056/NEJMoa2107934 2 comments science
Linking pages
- The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19’ is far from reality | Scientific Reports https://www.nature.com/articles/s41598-022-26053-w 179 comments
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic: Cell https://www.cell.com/cell/fulltext/S0092-8674(21)01495-1?rss=yes 54 comments
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2116044 2 comments
- Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant | GSK https://www.gsk.com/en-gb/media/press-releases/sotrovimab-retains-activity 1 comment
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2116846 0 comments
Linked pages
Related searches:
Search whole site: site:doi.org
Search title: Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab | NEJM
See how to search.